Vuzix Corp
Business
Vuzix Corp designs, manufactures, and markets AI-powered Smart Glasses, waveguides, and augmented reality technologies for enterprise, medical, defense, security, and select consumer markets. Its main products and services include near-eye displays, heads-up displays, wearable computing devices, proprietary waveguide optics, display engines, white-labeled reference designs, engineering services, and logistics mobility software (Mobilium®) for Smart Glasses integration. Key business activities comprise Vuzix-branded Smart Glasses, waveguide and display engine OEM/ODM supply and engineering services, and a software/app ecosystem supporting hardware deployments. The company sells globally via direct sales, VARs, distributors, OEM/ODM partnerships, and online stores, with sales presence in the U.S., Japan, Europe and other international markets.
Summary from filing dated 2025-03-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Sales | 6 | 6 | 12 | 12 | 13 | |
| Cost of Sales - Depreciation and Amortization | 677,931 | 734,456 | 886,117 | 799,317 | 1 | |
| Total Cost of Sales | 7 | 11 | 15 | 10 | 12 | |
| Gross Loss | −1 | −6 | −3 | 1 | 2 | |
| Research and Development | 13 | 10 | 12 | 13 | 12 | |
| Selling and Marketing | 5 | 8 | 13 | 8 | 6 | |
| General and Administrative | 12 | 17 | 19 | 21 | 23 | |
| Depreciation and Amortization | 2 | 3 | 4 | 2 | 988,104 | |
| Loss on Goodwill and Other Intangible Asset Impairment | — | — | 2 | — | — | |
| Loss on Fixed Asset Disposal | 106,898 | 27,654 | 0 | 35,350 | 183,614 | |
| Impairment on Intangible Asset and Equity Investment | — | 30 | — | — | — | |
| Impairment of Patents and Trademarks | 0 | 0 | 41,869 | 97,675 | 80,163 | |
| Total Operating Expenses | 31 | 68 | 50 | 44 | 42 | |
| Loss From Operations | −33 | −74 | −52 | −42 | −40 | |
| Investment Income | 672,276 | 591,319 | 2 | 1 | 53,511 | |
| Other Taxes | 23,054 | 59,335 | −230,973 | −212,997 | — | |
| Foreign Exchange Loss | −60,564 | −217,317 | −44,062 | −180,589 | −143,196 | |
| Impairment Loss on Equity Investment | −400,000 | 0 | 0 | — | — | |
| Utility Improvement Refund | — | — | 208,271 | — | — | |
| Total Other Income, Net | 234,766 | 433,337 | 2 | 1 | −397,053 | |
| Loss Before Provision for Income Taxes | −32 | −74 | −50 | −41 | −40 | |
| Provision for Income Taxes | 0 | 0 | 0 | — | — | |
| Preferred Stock Dividends | −62,333 | — | — | — | — | |
| Loss Attributable to Common Shareholders - Basic | −32 | −74 | −50 | −41 | −40 | |
| Loss Attributable to Common Shareholders - Diluted | −32 | −74 | −50 | — | — | |
| Basic Net Loss per Common Share | −0.42 | −1.08 | −0.79 | −0.64 | −0.66 | |
| Diluted Net Loss per Common Share | −0.42 | −1.08 | −0.79 | −0.64 | −0.66 | |
| Weighted-average Shares Outstanding - Basic | 78 | 68 | 63 | 64 | 61 | |
| Weighted-average Shares Outstanding - Diluted | 78 | 68 | 63 | 64 | 61 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | 21 | — | 18 | 27 | 73 | |
| Accounts Receivable, net of allowance for credit losses of $46,000 at December 31, 2025 and $89,000 at December 31, 2024 | 2 | — | 2 | 4 | 4 | |
| Accrued Revenues in Excess of Billings | 533,665 | — | 673,498 | 165,771 | 269,129 | |
| Other Receivables | 379,615 | — | — | — | — | |
| Inventories, Net | 2 | — | 5 | 9 | 11 | |
| Manufacturing Vendor Prepayments | 256,090 | — | 372,081 | 403,801 | 998,671 | |
| Prepaid Expenses and Other Assets | 1 | — | 1 | 1 | 2 | |
| Total Current Assets | 27 | — | 27 | 42 | 91 | |
| Fixed Assets, Net | 8 | — | 8 | 8 | 4 | |
| Operating Lease Right-of-Use Assets, Net | 1 | 1 | 494,236 | 301,185 | 956,165 | |
| Patents and Trademarks, Net | 3 | — | 3 | 3 | 2 | |
| Technology Licenses, Net | 559,973 | — | 761,043 | 27 | 30 | |
| Other Assets, Net | 327,778 | — | 844,445 | 1 | 950,000 | |
| Total Assets | 40 | — | 39 | 86 | 131 | |
| Accounts Payable | 685,010 | — | 538,221 | 2 | 1 | |
| Unearned Revenue | 62,361 | — | 125,901 | 18,839 | 29,064 | |
| Accrued Expenses | 4 | — | 945,752 | 2 | 2 | |
| Other Taxes Payable | 49,513 | — | 8,163 | 46,727 | 214,997 | |
| Operating Lease Right-of-Use Liabilities | 500,911 | — | 494,236 | 163,513 | 651,011 | |
| Total Current Liabilities | 5 | — | 2 | 5 | 15 | |
| Operating Lease Right-of-Use Liability | 502,114 | — | — | 137,672 | 305,154 | |
| Total Liabilities | 5 | — | 2 | 5 | 16 | |
| Preferred Stock - $0.001 Par Value, 5,000,000 Shares Authorized; 419,959 and zero Shares of Series B Preferred Stock Issued and Outstanding as of December 31, 2025 and December 31, 2024 | 10 | — | — | — | — | |
| Common Stock - $0.001 Par Value, 200,000,000 shares authorized; 81,679,367 shares issued and 81,099,695 shares outstanding as of December 31, 2025 and 100,000,000 shares authorized; 76,553,694 shares issued and 75,974,022 shares outstanding as of December 31, 2024 | 81,680 | — | 76,553 | 65,304 | 63,783 | |
| Additional Paid-in Capital | 427 | — | 407 | 377 | 361 | |
| Accumulated Deficit | −400 | — | −368 | −294 | −244 | |
| Treasury Stock, at cost, 579,672 shares as of December 31, 2025 and December 31, 2024 | −2 | — | −2 | −2 | −2 | |
| Total Stockholders' Equity | 25 | — | 37 | 81 | 115 | |
| Total Liabilities, Mezzanine Equity, and Stockholders' Equity | 40 | — | 39 | 86 | 131 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net Loss | −32 | −74 | −50 | −41 | −40 | |
| Depreciation and Amortization | 3 | 4 | 5 | 3 | 2 | |
| Stock-Based Compensation | 5 | 12 | 13 | 16 | 17 | |
| Allowance for Credit Losses | — | 977,363 | 2 | — | — | |
| Inventory Reserves for Obsolescence | 503,400 | 4 | 4 | 290,405 | 519,950 | |
| Impairment on Goodwill, Intangible Assets, and Equity Investments | 400,000 | 30 | 2 | — | — | |
| Accounts Receivable | −17,917 | 1 | −2 | −1 | −853,547 | |
| Accrued Revenues in Excess of Billings | 139,833 | −507,727 | 103,358 | −269,129 | — | |
| Other Receivables | −379,615 | 208,271 | 258,434 | — | — | |
| Inventories | 2 | 19,287 | −2 | 593,608 | −7 | |
| Manufacturing Vendor Prepayments | 115,991 | 31,720 | 594,870 | −494,620 | −19,019 | |
| Prepaid Expenses and Other Assets | 7,702 | 271,399 | 167,837 | −95,244 | −526,825 | |
| Accounts Payable | 146,789 | −1 | 358,883 | −843,015 | 537,607 | |
| Accrued Expenses | 2 | −1 | 745,904 | 251,231 | 436,276 | |
| Unearned Revenue | −63,540 | 107,062 | −10,225 | 1,268 | −13,355 | |
| Income and Other Taxes Payable | 41,350 | −38,564 | −168,270 | 94,755 | 10,589 | |
| Net Cash Flows Used in Operating Activities | −19 | −24 | −26 | −25 | −27 | |
| Purchases of Fixed Assets | −2 | −1 | −5 | −2 | −4 | |
| Investments in Patents and Trademarks | −554,816 | −560,958 | −632,483 | −499,031 | −593,184 | |
| Investments in Licenses | — | −1 | −11 | −17 | — | |
| Investments in Software Development | — | — | −125,000 | −125,000 | −250,000 | |
| Investment in Atomistic | — | — | −3 | — | — | |
| Investments in Other Equity Assets | −50,000 | — | −200,000 | −17 | −200,000 | |
| Net Cash Flows Used in Investing Activities | −3 | −3 | −19 | −21 | −5 | |
| Proceeds from Sale of Preferred and Common Stock to Quanta | 10 | 10 | — | — | — | |
| Proceeds from Exercise of Stock Options | 106,843 | 110,760 | 21,196 | 57,712 | 782,277 | |
| Proceeds from ATM Program, Net | 14 | 8 | — | — | 92 | |
| Purchase of Treasury Stock | — | — | −470,757 | −2 | — | |
| Net Cash Flows Provided by (Used in) Financing Activities | 24 | 18 | −449,561 | −2 | 116 | |
| Net Increase (Decrease) in Cash and Cash Equivalents | 3 | −8 | −46 | −48 | 84 | |
| Non-Cash Investment in Licenses | — | — | 1 | 12 | 1 | |
| Investment in Atomistic - Equity issued | — | 181,675 | 3 | — | — | |
| Accrued Preferred Dividends included in Accrued Expenses | 39,923 | — | — | — | — | |
| Depreciation and Amortization included in Research and Development Expense | 869,361 | 201,070 | 201,147 | — | — | |
| Stock-Based Compensation Expense - Expensed less Previously Issued | — | — | 92,454 | 61,824 | −1 | |
| Purchases of Fixed Assets included in Accrued Expenses | 723,023 | — | — | — | — |